Literature DB >> 17467249

Defining the need for breast cancer radiotherapy in the general population: a criterion-based benchmarking approach.

M Kerba1, Q Miao, J Zhang-Salomons, W Mackillop.   

Abstract

AIMS: Determining the appropriate rate of radiotherapy is important for ensuring optimal radiotherapy utilisation and accessibility. A criterion-based benchmark (CBB) was developed for estimating the need for radiotherapy in incident breast cancer cases. Our primary objective was to compare an evidence-based estimate (Ebest) of need against the CBB. These estimates were then compared with radiotherapy rates in Ontario, Canada and the USA. Surgical rates were also examined.
MATERIALS AND METHODS: Benchmarks were defined in Ontario as communities in proximity to cancer centres and without long waiting lists. Patient data from 1997 to 2001 were prospectively collected from radiotherapy cancer centres. Surgical data were obtained from the Canadian Institute for Health Information database. The public use file of Surveillance, Epidemiology and End Results (SEER) described treatment in the USA.
RESULTS: In total, 4241 cases of breast cancer were diagnosed in benchmark communities. The overall radiotherapy rate by Ebest was 64.0% (95% confidence interval: 58.1-69.8%) compared with the CBB of 60.7% (59.3-62.1%). In comparison, Ontario's overall radiotherapy rate was 55.6% (55.0-56.1%) and in SEER it was 49.3% (48.9-49.6%). Adjuvant radiotherapy rates after lumpectomy were 100% in Ebest and 83.6% (82.0-85.1%) by the CBB. The Ebest and CBB post-mastectomy rates were 21.9% (20.6-23.3%) and 34.6% (32.5-36.7%), respectively. Observed post-lumpectomy radiotherapy rates were 75.1% in Ontario and 65.3% in SEER. Post-mastectomy radiotherapy rates were 29.5% in Ontario and 17.0% in SEER.
CONCLUSIONS: CBB provides a reasonable estimate of the overall need for radiotherapy in breast cancer. Observed radiotherapy rates in Ontario and the USA suggest an age-related decrease in the use of radiotherapy. The benchmark estimate suggests a shortfall of adjuvant breast radiotherapy utilisation in Ontario.

Entities:  

Mesh:

Year:  2007        PMID: 17467249     DOI: 10.1016/j.clon.2007.03.013

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


  6 in total

1.  Helical tomotherapy in patients with breast cancer and complex treatment volumes.

Authors:  Ricardo Cendales; Luis Schiappacasse; Franco Schnitman; Graciela García; Hugo Marsiglia
Journal:  Clin Transl Oncol       Date:  2011-04       Impact factor: 3.405

2.  Cross-disciplinary research in cancer: an opportunity to narrow the knowledge-practice gap.

Authors:  R Urquhart; E Grunfeld; L Jackson; J Sargeant; G A Porter
Journal:  Curr Oncol       Date:  2013-12       Impact factor: 3.677

3.  Evaluation of the utilization of external radiotherapy in the treatment of localized prostate cancer in Andalusia, Spain.

Authors:  José Expósito; Isabel Linares; Isabel Castillo; Miguel Martínez; Pilar Vargas; Ismael Herruzo; José Antonio Medina; Amalia Palacios; Eloísa Bayo; Francisco Peracaula; Javier Jaén; José Antonio Sánchez; María José Ortiz
Journal:  Radiat Oncol       Date:  2015-12-30       Impact factor: 3.481

Review 4.  Barriers to accessing radiation therapy in Canada: a systematic review.

Authors:  Caitlin Gillan; Kaleigh Briggs; Alejandro Goytisolo Pazos; Melanie Maurus; Nicole Harnett; Pamela Catton; David Wiljer
Journal:  Radiat Oncol       Date:  2012-10-12       Impact factor: 3.481

5.  How do surgeons decide to refer patients for adjuvant cancer treatment? Protocol for a qualitative study.

Authors:  Robin Urquhart; Cynthia Kendell; Joan Sargeant; Gordon Buduhan; Paul Johnson; Daniel Rayson; Eva Grunfeld; Geoffrey A Porter
Journal:  Implement Sci       Date:  2012-10-25       Impact factor: 7.327

6.  Using relative survival measures for cross-sectional and longitudinal benchmarks of countries, states, and districts: the BenchRelSurv- and BenchRelSurvPlot-macros.

Authors:  Christian O Jacke; Iris Reinhard; Ute S Albert
Journal:  BMC Public Health       Date:  2013-01-14       Impact factor: 3.295

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.